ORIC Pharmaceuticals Boosts Talent Acquisition with Strategic Inducement Grants for New Employees
- ORIC Pharmaceuticals grants 29,600 stock options and 4,800 restricted stock units to attract new talent in 2025.
- The inducement grants align new employees' interests with ORIC's long-term success in combating cancer resistance.
- ORIC focuses on developing innovative cancer therapies, including ORIC-114 and ORIC-944, to improve patient outcomes.
ORIC Pharmaceuticals Strengthens Talent Pool with Inducement Grants
ORIC Pharmaceuticals, Inc., a clinical-stage oncology company based in South San Francisco and San Diego, announces strategic inducement grants aimed at attracting new talent to its innovative cancer treatment initiatives. On February 7, 2025, ORIC reveals the granting of 29,600 non-qualified stock options and 4,800 restricted stock units to two non-executive employees who commenced their roles in January 2025. This move reflects the company’s commitment to fostering a skilled workforce capable of driving forward its mission to combat therapeutic resistance in cancer. The grants, which are part of the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, are contingent upon the new employees’ continued tenure through the vesting schedule, further aligning their interests with the long-term success of the company.
The stock options are priced at the closing price of ORIC's common stock on February 3, 2025, and will follow a structured vesting schedule. Specifically, 25% of the options will vest after one year, with the remaining shares vesting monthly thereafter. In addition, the restricted stock units are set to vest in three equal portions on each of the first three anniversaries from the grant date. This strategic initiative receives approval from ORIC's Compensation Committee and adheres to Nasdaq regulations, underscoring the company’s proactive approach to incentivizing talent acquisition in a competitive healthcare landscape.
ORIC Pharmaceuticals is dedicated to developing cutting-edge therapies that target the mechanisms of resistance in various cancers. Among its promising clinical candidates are ORIC-114, designed to inhibit specific mutations in genetically defined cancers, and ORIC-944, which focuses on treating prostate cancer through the allosteric inhibition of the polycomb repressive complex 2. The company’s research and development efforts are centered on precision medicine, addressing critical cancer resistance mechanisms to improve patient outcomes. By enhancing its workforce through strategic inducement grants, ORIC positions itself for continued innovation and leadership in the oncology sector.
In addition to its talent acquisition efforts, ORIC Pharmaceuticals emphasizes the importance of ongoing communication with stakeholders. The company invites interested parties to explore further details on its website and follow its updates on social media platforms. Alongside these developments, ORIC includes cautionary notes regarding forward-looking statements, highlighting the potential impacts of their clinical developments and product candidates as they navigate the complexities of the oncology market.